A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

Promrat, Kittichai, Lutchman, Glen, Uwaifo, Gabriel I., Freedman, Renee J., Soza, Alejandro, Heller, Theo, Doo, Edward, Ghany, Marc +6 more·2004·Hepatology
DOI 10.1002/hep.20012

Cited by (722)

Items 401–500 of 722

  1. Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review
    Norberto Carlos Chávez-Tapia · 2006 · World Journal of Gastroenterology
  2. Glitazonas e síndrome metabólica: mecanismos de ação, fisiopatologia e indicações terapêuticas
    Marília Brito Gomes · 2006 · Arquivos Brasileiros de Endocrinologia & Metabologia
  3. Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin
    Mingyan Zhou, Aimin Xu, Karen S.L. Lam, Paul Kwong Hang Tam, Chi‐Ming Che, Lawrence Chan, In‐Kyu Lee, Donghai Wu, Yu Wang · 2010 · Journal of Hepatology
  4. Fatty liver disease
    Elizabeth M. Brunt, Brent A. Neuschwander‐Tetri, Alastair D. Burt · 2011 · Elsevier eBooks
  5. Data on Adiponectin from 2010 to 2020: Therapeutic Target and Prognostic Factor for Liver Diseases?
    Misaq Heydari, María Eugenia Cornide‐Petronio, Mónica B. Jiménez‐Castro, Carmen Peralta · 2020 · International Journal of Molecular Sciences
  6. Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: Relation to liver, muscle and regional body fat content
    Elizabeth Louise Thomas, Elizabeth Louise Potter, Isabella Tosi, Julie A. Fitzpatrick, Gavin Hamilton, Vian Amber, Robert I. Hughes, Christopher North, Paul Holvoet, Mary Seed et al. · 2007 · Atherosclerosis
  7. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD)
    Ignazio Grattagliano, Agostino Di Ciaula, Jacek Baj, Emilio Molina‐Molina, Harshitha Shanmugam, Gabriella Garruti, David Q.‐H. Wang, Piero Portincasa · 2021 · Methods in molecular biology
  8. Dietary curcumin restores insulin homeostasis in diet-induced obese aged mice
    Su‐Jeong Lee, Prabha Chandrasekran, Caio Henrique Mazucanti, Jennifer F. O’Connell, Josephine Mary Egan, Yoo Kim · 2022 · Aging
  9. Thiazolidinediones for the Treatment in NASH
    Curtis Kent Argo, Julia C. Iezzoni, Abdullah M. S. Al‐Osaimi, Stephen Hugh Caldwell · 2009 · Journal of Clinical Gastroenterology
  10. Effect of Alcohol on Viral Hepatitis and Other Forms of Liver Dysfunction
    Sripriya Balasubramanian, Kris V. Kowdley · 2005 · Clinics in Liver Disease
  11. Glitazones and the management of insulin resistance: what they do and how might they be used
    DANIEL F. EINHORN, Vanita R. Aroda, Robert R. Henry · 2004 · Endocrinology and Metabolism Clinics of North America
  12. State of the art
    Michelle Y. Pearlman, Rohit Seth Loomba · 2014 · Current Opinion in Gastroenterology
  13. Inhibitory effect of G inkgo biloba extract on fatty liver: Regulation of carnitine palmitoyltransferase 1a and fatty acid metabolism
    Shi Dong Wang, Zuoquan Xie, Jia Chen · 2012 · Journal of Digestive Diseases
  14. Emerging drugs for non-alcoholic fatty liver disease
    Alessandro Federico, Marco Niosi, C. Del Vecchio Blanco, C. Loguercio · 2008 · Expert Opinion on Emerging Drugs
  15. Fatty Liver Disease
    DINA G. TINIAKOS, Quentin Mark Anstee, Alastair D. Burt · 2017 · Elsevier eBooks
  16. Inflammatory Markers in Relation to Nonalcoholic Fatty Liver Disease in Urban South Indians
    Kuppan Gokulakrishnan, Ranjit Mohan Anjana, Mohan Deepa, Prabu Paramasivam, Sathishkumar Chandrakumar, Kaliyaperumal Velmurugan, Viswanathan Mohan · 2011 · Diabetes Technology & Therapeutics
  17. Pathobiological and molecular connections involved in the high fructose and high fat diet induced diabetes associated nonalcoholic fatty liver disease
    Ekta, Manisha Gupta, Amarjot Kaur, Thakur Gurjeet Singh, Onkar Bedi · 2020 · Inflammation Research
  18. Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials
    Kai Wei Lee, Navin Kumar Devaraj, Siew Mooi Ching, Sajesh Kalkandi Veettil, Fan Kee Hoo, Inas Deuraseh, Man Jun Soo · 2021 · Oman Medical Journal
  19. The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review
    Andrew Kamsoko Ndakotsu, Govinathan Vivekanandan · 2022 · Cureus
  20. Nonalcoholic Fatty Liver Disease
    Arun Jayant Sanyal · 2004 · Clinics in Liver Disease
  21. Review: Non-alcoholic fatty liver disease: natural history, pathogenesis and treatment
    Norma C. McAvoy, James Ferguson, Ian W Campbell, Peter Clive Hayes · 2006 · The British Journal of Diabetes
  22. Sirt1 and Sirt6 Mediate Beneficial Effects of Rosiglitazone on Hepatic Lipid Accumulation
    Soo Jin Yang, Jung Mook Choi, Eugene Chang, Sung Woo Park, Cheol-Young Park · 2014 · PLoS ONE
  23. Polycystic ovary syndrome
    Erian Mikhail, Dennis Cope · 2016 · Nature Reviews Disease Primers
  24. Nonalcoholic Fatty Liver Disease
    Samer Gawrieh · 2016 · Springer eBooks
  25. N-3 polyunsaturated fatty acids increase hepatic fibroblast growth factor 21 sensitivity via a PPAR-γ-β-klotho pathway
    Wenqi Yang, Xu Chen, Yan Liu, Ming Chen, Xinwei Jiang, Tianran Shen, Qing Li, Yan Yang, Wenhua Ling · 2017 · Molecular Nutrition & Food Research
  26. Selective inhibition of activated stellate cells and protection from carbon tetrachloride-induced liver injury in rats by a new PPARγ agonist KR62776
    Myung‐Ae Bae, Sang Dal Rhee, Won Hoon Jung, Jin Hee Ahn, Byoung‐Joon Song, Hyae Gyeong Cheon · 2010 · Archives of Pharmacal Research
  27. Review: Advances in the treatment of nonalcoholic fatty liver disease
    Sanjeev R. Mehta · 2010 · Therapeutic Advances in Endocrinology and Metabolism
  28. Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity
    Peter Wiesli, René L. Bernays, Michael Brändle, Cornelia Zwimpfer, Heidi Seiler, Jürgen Zapf, Giatgen A. Spinas, Christoph Schmid · 2004 · Clinica Chimica Acta
  29. Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression
    Jing Wu, Miaoyun Zhao, Hao Zheng · 2010 · Acta Pharmacologica Sinica
  30. Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease
    Małgorzata Saryusz‐Wolska, Elektra Szymańska‐Garbacz, Maciej Jabłkowski, Jolanta Białkowska, Maciej Pawłowski, Ewa Kwiecińska, Aleksandra Omulecka, Anna Borkowska, Anna Ignaczak, Jerzy Maksymilian Loba et al. · 2011 · Polskie Archiwum Medycyny Wewnętrznej
  31. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research
    Aline Gottlieb, Wesal Mosthael, Jan‐Peter Sowa, Ali E. Canbay · 2018 · Digestion
  32. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes
    Simona Cernea, Avivit Cahn, Itamar Raz · 2017 · Expert Review of Clinical Pharmacology
  33. Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome
    Simona Moscatiello, Raffaella Di Luzio, Anna Simona Sasdelli, Giulio Marchesini · 2011 · Expert Opinion on Pharmacotherapy
  34. SREBP1 interaction with prelamin A forms: A pathogenic mechanism for lipodystrophic laminopathies
    Nadir M. Maraldi, Cristina Capanni, Giovanna Lattanzi, Daria Camozzi, Andrea Facchini, Francesco A. Manzoli · 2007 · Advances in Enzyme Regulation
  35. Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment.
    Joel Z. Stengel, Stephen A. Harrison · 2006 · Europe PMC (PubMed Central)
  36. Review article: the treatment of fatty liver disease associated with the metabolic syndrome
    Giulio Marchesini, Silvia Natale, Rita Manini, F. Agostini · 2005 · Alimentary Pharmacology & Therapeutics
  37. Thiazolidinediones
    Kathryn Reynolds, Ronald B Goldberg · 2006 · Treatments in Endocrinology
  38. Treatment of non-alcoholic fatty liver disease with focus on emerging drugs
    Giulio Marchesini, Simona Moscatiello, F. Agostini, Nicola Villanova, Davide Festi · 2011 · Expert Opinion on Emerging Drugs
  39. Tetrahydroxanthohumol, a xanthohumol derivative, attenuates high-fat diet-induced hepatic steatosis by antagonizing PPARγ
    Yang Zhang, Gerd Bobe, Cristobal L. Miranda, Malcolm B. Lowry, Victor L. Hsu, Christiane V. Löhr, Carmen P. Wong, Donald Β. Jump, Matthew M. Robinson, Thomas J. Sharpton et al. · 2021 · eLife
  40. Non-alcoholic fatty liver disease
    Neeraj B. Bhala, Timothy Usherwood, Jacob George · 2009 · BMJ
  41. Non-alcoholic steatohepatitis: An update in pathophysiology, diagnosis and therapy
    Hossein Khedmat, Saeed Taheri · 2011 · Hepatitis Monthly
  42. Pharmacogenetics of Thiazolidinedione Therapy
    Christina L. Aquilante · 2007 · Pharmacogenomics
  43. New treatments for nonalcoholic fatty liver disease
    Stephen A. Harrison · 2006 · Current Gastroenterology Reports
  44. Hepatitis C and steatosis
    Anouk T Dev, Keyur Patel, John G. McHutchison · 2004 · Clinics in Liver Disease
  45. NAFLD treatment: Cognitive-behavioral therapy has entered the arena
    Giulio Marchesini, Alessandro Suppini, Gabriele Forlani · 2005 · Journal of Hepatology
  46. Dual Peroxisome Proliferator-Activated Receptor-??/?? Agonists
    Harrihar A. Pershadsingh · 2006 · Treatments in Endocrinology
  47. Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection
    Lindsay Matthews, David Erwin Kleiner, Cheryl L. Chairez, Maryellen McManus, Mary Jane Nettles, Kira Zemanick, Caryn Gee Morse, Debra Benator, Joseph A. Kovacs, Colleen M. Hadigan · 2015 · AIDS Research and Human Retroviruses
  48. Nonalcoholic Fatty Liver Disease and Liver Transplantation
    Tuan Anh Pham, Travis B. Dick, Michael Charlton · 2016 · Clinics in Liver Disease
  49. Life Style-Related Diseases of the Digestive System: Gene Expression in Nonalcoholic Steatohepatitis Patients and Treatment Strategies
    Masato Yoneda, Hiroki Endo, Yuichi Nozaki, Ayako Tomimoto, Toshio Fujisawa, Koji Fujita, Kyoko Yoneda, Hirokazu Takahashi, Satoru Saito, Tomoyuki Iwasaki et al. · 2007 · Journal of Pharmacological Sciences
  50. Recurrent Familial Hypobetalipoproteinemia–Induced Nonalcoholic Fatty Liver Disease After Living Donor Liver Transplantation
    Noboru Harada, Yuji Soejima, Akinobu Taketomi · 2009 · Liver Transplantation
  51. Advances in Epidemiology and Treatment of Type 2 Diabetes in Children
    Orit Pinhas‐Hamiel, Philip Scott Zeitler · 2005 · Advances in Pediatrics
  52. Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial
    Minyoung Lee, Sukchul Hong, Yongin Cho, Hyungjin Rhee, Min Heui Yu, Jae Hyun Bae, Yong‐ho Lee, Byung‐Wan Lee, Eun Seok Kang, Bong Soo · 2025 · BMC Medicine
  53. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease
    Swaytha Ganesh, Vinod K. Rustgi · 2016 · Clinics in Liver Disease
  54. Pharmacological therapy of nonalcoholic steatohepatitis
    Mariko Hojo, Sumio Watanabe · 2011 · Hepatology Research
  55. Liver Failure and Liver Disease
    Elwyn Elias · 2006 · Hepatology
  56. Third Annual World Congress on the Insulin Resistance Syndrome
    Zachary T. Bloomgarden · 2006 · Diabetes Care
  57. [Non-alcoholic fatty liver disease: a new challenge for cardiologists].
    Roberto Tarquini, Chiara Lazzeri, Maria Boddi, Fabio Marra, Rosanna Abbate, Gian Franco Gensini · 2010 · PubMed
  58. The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study
    Jiyun Park, Gyuri Kim, Bongsung Kim, Kyungdo Han, So Yoon Kwon, Sohee Park, You‐Bin Lee, Sang‐Man Jin, Jae Hyeon Kim · 2022 · Diabetes Research and Clinical Practice
  59. Validation of a diet‐induced Macaca fascicularis model of non‐alcoholic steatohepatitis with dietary and pioglitazone interventions
    Raul C. Camacho, David Polidori, Tao Chen, Bin Chen, Helen Han Hsu, Bin Gao, Mathieu Marella, Mariusz S. Lubomirski, Traymon Beavers, Javier Cabrera et al. · 2022 · Diabetes Obesity and Metabolism
  60. Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease
    Giampaolo P. Bianchi, Elisabetta Bugianesi, Jan Frystyk · 2010 · Digestive and Liver Disease
  61. Non-alcoholic steatohepatitis
    Brent A. Neuschwander‐Tetri · 2006 · Current Opinion in Endocrinology & Diabetes
  62. Non‐Alcoholic Fatty Liver Disease and Nutrition
    Stephen Hugh Caldwell, Curtis Kent Argo · 2011
  63. Polycystic Ovary Syndrome
    Alain Braillon · 2005 · New England Journal of Medicine
  64. Glucagon-like Peptide-1 Improves Fatty Liver and Enhances Thermogenesis in Brown Adipose Tissue via Inhibiting BMP4-Related Signaling Pathway in High-Fat-Diet-Induced Obese Mice
    Xingchun Wang, Bingwei Ma, Jiaqi Chen, Hui You, Chunjun Sheng, Peng Yang, Shen Qu · 2021 · International Journal of Endocrinology
  65. The Epidemic of Type 2 Diabetes Mellitus: Its Links to Obesity, Insulin Resistance, and Lipotoxicity
    Kenneth J. Cusi · 2009 · Humana Press eBooks
  66. Effect of Insulin versus Triple Oral Therapy on the Progression of Hepatic Steatosis in Type 2 Diabetes
    Ildiko Lingvay, Erin D. Roe, Jonathan Duong, David S. Leonard, Lidia S. Szczepaniak · 2012 · Journal of Investigative Medicine
  67. The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis
    Idilio Zamin, Ângelo Alves de Mattos, Ângelo Zambam de Mattos, Gabriela Perdomo Coral, Diogo Edele dos Santos, Cláudia Ramos Rhoden · 2010 · Arquivos de Gastroenterologia
  68. Nonalcoholic fatty liver disease: from clinical recognition to treatment
    Vassilios Sevastianos, Stephanos J. Hadziyannis · 2008 · Expert Review of Gastroenterology & Hepatology
  69. Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic.
    Marialena Mouzaki, Johane P. Allard · 2012 · Europe PMC (PubMed Central)
  70. Pathology of fatty liver: differential diagnosis of non-alcoholic fatty liver disease
    Matthew M. Yeh, Elizabeth M. Brunt · 2008 · Diagnostic histopathology
  71. Nonalcoholic Steatohepatitis (NASH)
    Qingyan Liu, David Erwin Kleiner · 2010 · Pathology Case Reviews
  72. Regulation of peroxisome proliferator-activated receptor- in liver fibrosis
    Liu Yang, Che–Chang Chan, Oh Sang Kwon, Songling Liu, Jason McGhee, Stephen A. Stimpson, Lihong Z. Chen, W. Wallace Harrington, William T. Symonds, Don C. Rockey et al. · 2006
  73. Novel therapeutic drug identification and gene correlation for fatty liver disease using high-content screening: Proof of concept
    Weijia Luo, Ting‐Yu Cheng, Keng-Ieng Wong, Woei-horng Fang, Keng-Mao Liao, Yun-Ting Hsieh, Kang‐Yi Su · 2018 · European Journal of Pharmaceutical Sciences
  74. EGCG mediated downregulation of NF-AT and macrophage infiltration in experimental hepatic steatosis
    Thulasi Raman Krishnan, Prema Velusamy, Ashokkumar Srinivasan et al. · 2014 · Experimental Gerontology
  75. Comparative study of liver injury induced by high-fat methionine- and choline-deficient diet in ICR mice originating from three different sources
    Seung‐Hyun Lee, Jae‐Hwan Kwak, Sou Hyun Kim, Tae Bin Jeong, Seung Won Son, Joung-Hee Kim, Yong Lim, Joon‐Yong Cho, Dae Youn Hwang, Kil‐Soo Kim et al. · 2019 · Laboratory Animal Research
  76. Nonalcoholic Fatty Liver Disease
    Puneet Puri, Arun Jayant Sanyal · 2012 · Elsevier eBooks
  77. Potential Role of Interleukin‐18 in Liver Disease Associated with Insulin Resistance
    Abel López‐Bermejo, Montserrat Bosch, Mónica Recasens, Josefina Biarnés, Eduardo Esteve, Roser Casamitjana, Joan Josep Vendrell, Wifredo Ricart, José Manuel Fernández‐Real · 2005 · Obesity Research
  78. Nonalcoholic steatohepatitis: Pathogenesis and treatment
    Sang Hoon Park · 2008 · The Korean Journal of Hepatology
  79. ABCD position statement on glitazones
    E. R. Higgs, AJ Krentz · 2004 · Practical Diabetes
  80. Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Leonie Gellrich, Daniel Merk · 2017 · Nuclear Receptor Research
  81. Pharmacological therapy for non‐alcoholic steatohepatitis: How efficient are thiazolidinediones?
    Vlad Ratziu, Loredana Pienar · 2011 · Hepatology Research
  82. Is Nonalcoholic Fatty Liver Disease in Children the Same Disease as in Adults?
    Evelyn Kanyu Hsu, Karen F. Murray · 2012 · Clinics in Liver Disease
  83. Fatty Liver Disease
    Elizabeth M. Brunt, DINA G. TINIAKOS · 2009 · Elsevier eBooks
  84. Comparison of Pioglitazone and Metformin Efficacy against Glucocorticoid Induced Atherosclerosis and Hepatic Steatosis in Insulin Resistant Rats
    Nagendra Nayak Im · 2017 · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
  85. Progress in promising anti-fibrotic therapies
    Rosanna Santoro, Alessandra Mangia · 2019 · Expert Review of Gastroenterology & Hepatology
  86. Association of ADIPOR2 With Liver Function Tests in Type 2 Diabetic Subjects
    Abel López‐Bermejo, P. Botas-Cervero, Francisco José Ortega, Elías Delgado, Maria García-Gil, Tohru Funahashi, Wifredo Ricart, José Manuel Fernández‐Real · 2008 · Obesity
  87. Mechanisms underlying nonalcoholic steatohepatitis
    Manal F. Abdelmalek, Anna Mae Diehl · 2006 · Drug Discovery Today Disease Mechanisms
  88. Plasma Plasminogen Activator Inhibitor-1 Levels and Nonalcoholic Fatty Liver in Individuals With Features of Metabolic Syndrome
    Gabriela Fernanda De Larrañaga, Silvia D. Perés Wingeyer, Mabel Nora Graffigna, Susana Belli, Karla Bendezú, Silvia Alvarez, Oscar A. Levalle, Hugo Alberto Fainboim · 2007 · Clinical and Applied Thrombosis/Hemostasis
  89. Non‐Alcoholic Fatty Liver Disease
    Chris Day · 2004
  90. Review: Treatment options for nonalcoholic fatty liver disease
    Shivakumar Chitturi · 2008 · Therapeutic Advances in Gastroenterology
  91. Thiazolidinediones and hepatic fibrosis: don’t wait too long
    Fabio Marra · 2006 · Gut
  92. The 6th Annual World Congress on the Insulin Resistance Syndrome
    Zachary T. Bloomgarden · 2009 · Diabetes Care
  93. The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition
    Yu Seol Lee, Jeong Su Park, Da Hyun Lee, Dong‐Kyu Lee, Sung Won Kwon, Byung‐Wan Lee, Soo Han Bae · 2018 · Frontiers in Endocrinology
  94. Nonalcoholic fatty liver disease and HIV infection
    Raphael B. Merriman · 2006 · Current HIV/AIDS Reports
  95. Pharmacological treatment of non-alcoholic steatohepatitis: The current evidence
    Maria Diakou, Evangelos N. Liberopoulos, Dimitri P. Mikhailidis, Epaminondas V. Tsianos, Andrew Kenneth Burroughs, Moses Elisaf · 2006 · Scandinavian Journal of Gastroenterology
  96. Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal
    Valério Nobili, Arun Jayant Sanyal · 2011 · Journal of Gastroenterology
  97. NASH Drug Development: Seeing the Light at the End of the Tunnel?
    Yong Q. Chen · 2023 · Journal of Clinical and Translational Hepatology
  98. Glitazones for human nonalcoholic steatohepatitis
    Raluca Pais, I Moraru, Vlad Ratziu · 2011 · Therapeutic Advances in Gastroenterology
  99. Therapy for Nonalcoholic Fatty Liver Disease
    Richard H. Moseley · 2008 · Journal of Clinical Gastroenterology
  100. Divergent effects of peroxisome proliferator–activated receptor‐γ ligands in human and mouse nonalcoholic steatohepatitis†‡
    Stephen Hugh Caldwell, Curtis Kent Argo · 2007 · Hepatology